The advanced cancer pain management market includes drugs and devices used in managing severe cancer pain. Cancer pain management has evolved significantly over the years with the introduction of novel pain management therapies such as transcutaneous electrical nerve stimulation (TENS), nerve blocks, cognitive behavioral therapy and radiation therapy in addition to opioids. Opioids such as morphine, fentanyl, oxycodone and hydrocodone continue to be the mainstay in advanced cancer pain management, however non-opioid therapies and interventional techniques are gaining popularity due to concerns over opioid misuse and addiction.
The Global Advanced Cancer Pain Management Market is estimated to be valued at USD 8.1 Bn in 2024 and is expected to reach USD 12.9 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.6% from 2024 to 2031.
Key players operating in the advanced cancer pain management are Pfizer, Teva Pharmaceuticals, Janssen Pharmaceuticals, Purdue Pharma, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Novartis AG and Seagen.
With the growing burden of Advanced Cancer Pain Management Market worldwide, there is tremendous opportunity in developing novel treatment options that are more effective than conventional therapies. Companies are investing heavily in pharmaceutical research and development to gain a competitive edge in the market. With respect to opportunities, there is a growing need for interventional pain therapies that can offer prolonged pain relief with minimal side effects.
Techniques like radiofrequency ablation, cryoablation and neurostimulation are minimally invasive and finding increased acceptance. There is also demand for easy to administer formulations such as transdermal patches and long acting injections that can improve patient compliance. Key players are also investing in expanding their geographic footprints in high growth emerging markets. For instance, Pfizer acquired Hospira to strengthen its biosimilar and generic injectable portfolio in international markets. Janssen's partnership with Cellectis is aimed at developing gene-edited CAR-T cells with potential application in various cancers including multiple myeloma.
Market Drivers
Increasing incidence and prevalence of cancer worldwide is a major growth driver for the advanced cancer pain management market. As per WHO, cancer burden is expected to grow by ~70% over the next two decades. Adequate pain management is a critical part of palliative care.
Market Restraints
stringent regulations pertaining to opioids amid concerns over addiction and abuse pose a challenge for market players. Additionally, the preference for alternative therapies and reluctance to use opioids in some regions like Asia Pacific limits market potential to a certain extent. High costs of novel therapies also restrain widespread adoption.
Segment Analysis
This market can be segmented based on disease type, treatment type and end user. By disease type, the advanced lung cancer segment dominates the market as lung cancer is one of the most common cancer globally and causes significant amount of pain. Palliative radiotherapy followed by opioids hold a major share of the treatment type segment. Palliative radiotherapy is preferred for pain relief as it specifically targets the tumor site. Among end users, hospitals form the largest segment as majority of advanced cancer pain management procedures are conducted in hospitals.
Global Analysis
North America holds the largest share in the global advanced cancer pain management market ascribing to growing burden of cancer, presence of well-established healthcare facilities and availability of advanced treatment options. Asia Pacific is expected to witness the highest growth during the forecast period owing to increasing incidence of cancer, rising awareness levels and improving healthcare infrastructure across developing countries. Countries like China and Japan are expected to significantly contribute to the Asia Pacific market. Rising government initiatives for healthcare modernization will further propel the regional market.
Get this Report in Japanese Language: 先進癌疼痛管理市場
Get this Report in Korean Language: 고급 암 통증 관리 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
